Overview
Malignant mesothelioma of the pleura is a highly aggressive and often fatal neoplasm primarily associated with asbestos exposure. It predominantly affects the pleural lining of the lungs, leading to symptoms such as chest pain, dyspnea, and pleural effusions. Given its poor prognosis and limited treatment options, early diagnosis and comprehensive management are crucial for improving patient outcomes. This condition significantly impacts clinical practice due to its rarity, diagnostic challenges, and the need for multidisciplinary care approaches. 123Pathophysiology
Malignant pleural mesothelioma arises from mesothelial cells lining the pleura, typically triggered by chronic exposure to asbestos fibers. These fibers induce chronic inflammation and genetic mutations, leading to uncontrolled proliferation of mesothelial cells. The molecular pathways involved include dysregulation of cell cycle control, apoptosis inhibition, and activation of oncogenic signaling cascades such as PI3K/AKT and RAS/RAF/MEK/ERK pathways. Epigenetic modifications and alterations in microRNA expression further contribute to tumor progression. Histologically, mesothelioma can be classified into three main subtypes—epithelial, sarcomatous, and biphasic—each with distinct biological behaviors and prognoses. Epithelial subtypes generally have better outcomes compared to sarcomatous types, which are more aggressive. 12Epidemiology
Malignant pleural mesothelioma has a global incidence that continues to rise, particularly in regions with historical asbestos exposure. The incidence rates vary geographically, with higher prevalence in industrialized countries like the UK, Europe, and Australia. It predominantly affects individuals aged 60-70 years, with a male predominance due to occupational exposure risks. The latency period between asbestos exposure and disease onset can span several decades, typically ranging from 30 to 50 years. Recent trends indicate increasing awareness and improved diagnostic techniques have contributed to higher reported incidence rates, though true incidence may still be underestimated. 123Clinical Presentation
Patients with malignant pleural mesothelioma often present with nonspecific symptoms initially, including persistent chest pain, dyspnea, and weight loss. Common clinical features include pleural effusion, leading to breathlessness and cough, and sometimes ascites or pericardial effusion. Advanced disease may manifest with more severe symptoms such as fatigue, cachexia, and neurological deficits if tumor spread occurs. Red-flag features include rapid symptom progression, unexplained weight loss, and signs of systemic involvement like jaundice or neurological symptoms, necessitating urgent diagnostic evaluation. 12Diagnosis
The diagnostic approach for malignant pleural mesothelioma involves a combination of imaging, cytology, and histopathology. Key steps include:Imaging: Chest CT and MRI to assess pleural thickening, masses, and effusions.
Cytology: Thoracentesis or pleural biopsy for pleural fluid analysis.
Histopathology: Definitive diagnosis through pleural biopsy (open or video-assisted thoracoscopic surgery) with immunohistochemical staining to differentiate mesothelioma from other malignancies.Specific Criteria and Tests:
Imaging Criteria: Pleural thickening >1 cm, pleural masses, or pleural effusion with atypical cells.
Cytology: Positive malignant cells in pleural fluid.
Histopathology: Pathological confirmation with positive markers such as calretinin, WT-1, and CK5/6.
TNM Staging: Utilize the International Mesothelioma Interest Group staging system to assess extent of disease.
Differential Diagnosis:
- Lung Cancer: Differentiated by histology and location.
- Metastatic Disease: Excluded by primary tumor identification and imaging characteristics.
- Benign Pleural Effusions: Ruled out by absence of malignant cells and clinical context.123
Management
First-Line Treatment
Trimodality Therapy:
Extrapleural Pneumonectomy (EPP): Considered in fit patients with resectable disease (T1-3, N0-1, M0).
- Procedure: Resection of the entire affected hemithorax, including lung, parietal pleura, pericardium, and diaphragm.
- Contraindications: Poor performance status, significant comorbidities, unresectable disease.
Neoadjuvant Chemotherapy:
- Regimen: Platinum-based (e.g., cisplatin with pemetrexed or gemcitabine).
- Duration: Typically three cycles before surgery.
- Monitoring: Regular blood counts, renal function, and toxicity assessment.Adjuvant Radiotherapy:
Technique: Intensity-modulated radiotherapy (IMRT) to minimize lung toxicity.
- Dose: Typically 54 Gy in 30 fractions.
- Target Volume: Entire hemithorax, including pleural folds and surgical sites.
- Monitoring: Pulmonary function tests, acute and late radiation toxicity.Second-Line and Refractory Disease
Chemotherapy: Post-progression, regimens like pemetrexed monotherapy or combination therapies (e.g., cisplatin with pemetrexed).
- Duration: Until disease progression or unacceptable toxicity.
- Monitoring: Regular imaging, blood counts, and symptom assessment.
Targeted Therapy: Emerging role for agents targeting specific molecular alterations (e.g., mesothelin).
- Considerations: Availability, patient selection based on biomarker status.
Clinical Trials: Encouraged for patients with refractory disease to access novel therapies.1235
Complications
Acute Complications
Perioperative Mortality: 5-10% in high-volume centers.
Major Morbidity: Atelectasis, respiratory failure, infections (e.g., empyema).
- Management Triggers: Close monitoring post-surgery, prompt intervention for signs of respiratory compromise or infection.Long-Term Complications
Radiation Toxicity: Pulmonary fibrosis, esophagitis, pericarditis.
- Management: Regular pulmonary function tests, symptomatic treatment.
Recurrence: High risk, typically within 10-18 months post-treatment.
- Monitoring: Regular imaging and clinical follow-up.Referral Indicators
Complex Comorbidities: Multidisciplinary team involvement for complex cases.
Symptom Management: Palliative care referral for symptom control.1234
Prognosis & Follow-Up
Expected Course: Median survival ranges from 12 to 35 months, varying by subtype and treatment modality.
Prognostic Indicators: Histology (epithelial better than sarcomatous), stage at diagnosis, performance status, and response to therapy.
Follow-Up Intervals: Every 3-6 months initially, reducing to every 6-12 months as disease stabilizes or progresses.
Monitoring: Regular imaging (CT/MRI), blood tests, and clinical assessments to monitor for recurrence and manage symptoms.123
Special Populations
Elderly Patients
Considerations: Functional status, comorbidities, and risk-benefit analysis of aggressive treatments.
Approach: Often managed with less invasive strategies or supportive care.Comorbidities
Impact: Significant comorbidities may limit surgical candidacy; multimodal therapy tailored to individual risk profiles.
Management: Multidisciplinary assessment to optimize comorbidities before aggressive interventions.124
Key Recommendations
Trimodality Therapy for Resectable Disease: Offer extrapleural pneumonectomy within a multimodal regimen (chemotherapy + radiotherapy) to fit patients with resectable mesothelioma (Evidence: Strong 12).
Neoadjuvant Chemotherapy: Use platinum-based chemotherapy regimens preoperatively to improve resectability and outcomes (Evidence: Strong 5).
Adjuvant Radiotherapy: Implement intensity-modulated radiotherapy post-EPP to enhance local control while minimizing lung toxicity (Evidence: Moderate 3).
Regular Follow-Up: Schedule follow-up imaging and clinical assessments every 3-6 months initially, reducing to every 6-12 months as disease stabilizes (Evidence: Moderate 12).
Consider Clinical Trials: Encourage enrollment in clinical trials for patients with refractory disease to access innovative treatments (Evidence: Expert opinion 5).
Multidisciplinary Care: Engage a multidisciplinary team for comprehensive management, especially in complex cases (Evidence: Expert opinion 12).
Palliative Care Integration: Integrate palliative care early to manage symptoms and improve quality of life (Evidence: Moderate 4).
Risk Stratification: Tailor treatment based on prognostic factors such as histology, stage, and performance status (Evidence: Moderate 23).
Avoid EPP in High-Risk Patients: Exercise caution with EPP in patients with significant comorbidities or poor performance status (Evidence: Moderate 4).
Monitor for Recurrence: Regularly monitor for early signs of recurrence, typically within 10-18 months post-treatment (Evidence: Moderate 12).References
1 Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J et al.. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. The Lancet. Oncology 2011. link70149-8)
2 Sugarbaker DJ, Garcia JP, Richards WG, Harpole DH, Healy-Baldini E, DeCamp MM et al.. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Annals of surgery 1996. link
3 Chi A, Liao Z, Nguyen NP, Howe C, Gomez D, Jang SY et al.. Intensity-modulated radiotherapy after extrapleural pneumonectomy in the combined-modality treatment of malignant pleural mesothelioma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011. link
4 Sharif S, Zahid I, Routledge T, Scarci M. Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma?. Interactive cardiovascular and thoracic surgery 2011. link
5 Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M et al.. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004. link
6 Yajnik S, Rosenzweig KE, Mychalczak B, Krug L, Flores R, Hong L et al.. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. International journal of radiation oncology, biology, physics 2003. link00287-6)